Hainan Honz Pharmaceutical Co Working Capital to Net Assets Ratio
Hainan Honz Pharmaceutical Co working capital to net assets ratio. Hainan Honz Pharmaceutical Co (300086) has a Working Capital to Net Assets ratio of -34.8% as of June 2026. Working capital of CN¥-308.85 Million (current assets of CN¥258.31 Million minus current liabilities of CN¥567.17 Million) is measured against net assets of CN¥887.65 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Hainan Honz Pharmaceutical Co to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hainan Honz Pharmaceutical Co (2007–2025)
Working capital to net assets ratio of Hainan Honz Pharmaceutical Co from 2007 to 2025. This chart shows how Hainan Honz Pharmaceutical Co's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of June 2026, the ratio stands at -34.8%, reflecting working capital of CN¥-308.85 Million against net assets of CN¥887.65 Million CNY. See 300086 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Hainan Honz Pharmaceutical Co Working Capital to Net Assets Ratio by Year (2007–2025)
Hainan Honz Pharmaceutical Co working capital to net assets ratio by year from 2007 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Hainan Honz Pharmaceutical Co from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Hainan Honz Pharmaceutical Co's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -30.3% | CN¥-279.01 Million | CN¥921.22 Million | CN¥304.48 Million | CN¥583.49 Million | ▼ -25.8 pp |
| 2024 | -4.5% | CN¥-52.61 Million | CN¥1.17 Billion | CN¥443.07 Million | CN¥495.68 Million | ▼ -21.1 pp |
| 2023 | 16.6% | CN¥228.76 Million | CN¥1.38 Billion | CN¥609.35 Million | CN¥380.59 Million | ▲ +4.4 pp |
| 2022 | 12.2% | CN¥165.95 Million | CN¥1.36 Billion | CN¥670.46 Million | CN¥504.51 Million | ▼ -2.9 pp |
| 2021 | 15.1% | CN¥234.98 Million | CN¥1.55 Billion | CN¥719.90 Million | CN¥484.92 Million | ▲ +7.1 pp |
| 2020 | 8.0% | CN¥128.20 Million | CN¥1.60 Billion | CN¥708.98 Million | CN¥580.78 Million | ▲ +5.8 pp |
| 2019 | 2.2% | CN¥35.57 Million | CN¥1.60 Billion | CN¥526.03 Million | CN¥490.46 Million | ▼ -11.3 pp |
| 2018 | 13.6% | CN¥224.33 Million | CN¥1.65 Billion | CN¥687.75 Million | CN¥463.42 Million | ▼ -46.2 pp |
| 2017 | 59.7% | CN¥1.15 Billion | CN¥1.92 Billion | CN¥1.41 Billion | CN¥265.92 Million | ▼ -4.2 pp |
| 2016 | 63.9% | CN¥1.20 Billion | CN¥1.87 Billion | CN¥1.47 Billion | CN¥275.77 Million | ▼ -1.7 pp |
| 2015 | 65.5% | CN¥1.21 Billion | CN¥1.84 Billion | CN¥1.42 Billion | CN¥214.60 Million | ▼ -0.2 pp |
| 2014 | 65.7% | CN¥1.19 Billion | CN¥1.80 Billion | CN¥1.27 Billion | CN¥86.86 Million | ▲ +1.7 pp |
| 2013 | 64.1% | CN¥1.16 Billion | CN¥1.81 Billion | CN¥1.25 Billion | CN¥88.86 Million | ▼ -3.9 pp |
| 2012 | 68.0% | CN¥1.27 Billion | CN¥1.87 Billion | CN¥1.37 Billion | CN¥91.19 Million | ▼ -1.2 pp |
| 2011 | 69.2% | CN¥1.28 Billion | CN¥1.85 Billion | CN¥1.39 Billion | CN¥106.44 Million | ▼ -19.0 pp |
| 2010 | 88.2% | CN¥1.61 Billion | CN¥1.83 Billion | CN¥1.68 Billion | CN¥70.11 Million | ▲ +36.9 pp |
| 2009 | 51.3% | CN¥123.43 Million | CN¥240.49 Million | CN¥176.62 Million | CN¥53.20 Million | ▲ +7.8 pp |
| 2008 | 43.5% | CN¥65.43 Million | CN¥150.41 Million | CN¥121.35 Million | CN¥55.93 Million | ▼ -17.2 pp |
| 2007 | 60.7% | CN¥70.29 Million | CN¥115.89 Million | CN¥95.97 Million | CN¥25.68 Million | — |